E
Emendo Biotherapeutics
Biotech & Life Sciences · New York City, United States · Founded 2015
Develops next-generation gene editing using synthetic biology to address untreatable diseases MoreLess
Emendo Biotherapeutics is a biotechnology startup that is revolutionizing the field of gene editing. The company utilizes a novel approach to the CRISPR-Cas9 system, a technology that allows scientists to edit genes within organisms. Emendo Biotherapeutics' unique approach involves understanding each genetic disease individually and then devising an optimal editing strategy. This approach is a departure from the traditional use of CRISPR, which has been limited by its inability to fully address complex genetic diseases.
The company serves clients in the healthcare and medical research sectors, providing them with innovative solutions for genetic diseases. Emendo Biotherapeutics operates in the biotechnology market, a sector that is expected to grow significantly due to the increasing prevalence of diseases that require genetic intervention.
Emendo Biotherapeutics' business model revolves around the development and commercialization of its unique CRISPR solutions. The company makes money by licensing its technology to healthcare and research institutions. Additionally, it also generates revenue through partnerships with pharmaceutical companies that are interested in using its technology for drug development.
In summary, Emendo Biotherapeutics is a pioneering biotech startup that is pushing the boundaries of gene editing. Its unique approach to CRISPR-Cas9 technology has the potential to make a significant impact on the treatment of genetic diseases.
Keywords: Biotechnology, Gene Editing, CRISPR-Cas9, Genetic Diseases, Healthcare, Medical Research, Novel Approach, Licensing, Partnerships, Drug Development.
Company overview
Emendo Biotherapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2015
- Headquarters
- New York City, United States
- Employees
- 40
- Open positions
- None listed
- Dealroom signal
- 64.3
Valuation & funding
Emendo Biotherapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Apr 2023 | $10M | $305M | AnGes | — |
| LATE VCOther financing | Jun 2022 | $30M | $305M | AnGes | — |
| LATE VCOther financing | Jun 2021 | $41M | $305M | Undisclosed | — |
| LATE VCOther financing | Dec 2020 | $21M | $305M | Undisclosed | — |
| SERIES BOther financing | Jan 2020 | $61M | $244M | AnGes | ↗ |
| SERIES AOther financing | Sep 2016 | OrbiMed · Takeda | — |
Growth signals
Emendo Biotherapeutics website traffic
Latest recorded traffic for Emendo Biotherapeutics is 960 monthly website visits, down 4% over the last three months. Emendo Biotherapeutics's team grew 2.6% over the past year.
Comparisons
Emendo Biotherapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Emendo Biotherapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Emendo Biotherapeutics has talent and traffic
In the news
Latest news about Emendo Biotherapeutics
Recent press, funding announcements, and product moves mentioning Emendo Biotherapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Emendo Biotherapeutics
An AI-synthesized read of the highest-engagement posts about Emendo Biotherapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Emendo Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.